Open Label 1b/2a Trial of a Combination of IPH2201 and Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Aug 2019
Price : $35 *
At a glance
- Drugs Monalizumab (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Innate Pharma
- 05 Aug 2019 Planned End Date changed from 1 Jun 2019 to 1 Oct 2019.
- 20 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2015 Status changed from not yet recruiting to recruiting according to an Innate Pharma media release.